Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 294

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 294
---
    444,009

    $
    985,801

    Reconciliation of cash, cash equivalents and restricted cash:

    Cash and cash equivalents
     
    $
    1,103,010

    $
    428,430

    $
    966,777

    Restricted cash in other assets

    15,579

    15,579

    19,024

    Total cash, cash equivalents and restricted cash
     
    $
    1,118,589

    $
    444,009

    $
    985,801

    Supplemental disclosure of cash flow information:

    Cash paid during the period for interest
     
    $
    15,856

    $
    15,923

    $
    44,418

    Cash paid during the period for income taxes
     
    $
    22,587

    $
    15,081

    $
    1,695

    Supplemental schedule of non-cash activities:

    Common stock issued for conversion or exchange of 2024 Notes
     
    $
    105,757

    $
    693,377

    $
    —

    Intangible assets and property and equipment included in accounts payable and accrued expenses
     
    $
    42,740

    $
    33,339

    $
    6,765

    Lease liabilities arising from obtaining right of use assets
     
    $
    35,361

    $
    80,203

    $
    40,006

    Capitalized stock-based compensation and depreciation as inventory
     
    $
    28,549

    $
    —

    $
    —

    Lease liabilities terminated
     
    $
    2,381

    $
    —

    $
    3,807

See accompanying notes to consolidated financial statements.

F-7

Sarepta Therapeutics, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. ORGANIZATION AND NATURE OF BUSINESSSarepta Therapeutics, Inc. (together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying its proprietary, highly-differentiated and innovative technologies, and through collaborations with its strategic